The efficacy and saftey results from the OPTIMUM study, a Phase III superiority study of PONVORY® vs. teriflunomide 14mg in patients with RMS
An overview of PONVORY® that can aid in your treatment decisions for patients with RMS
Find answers to common questions surrounding PONVORY® here
We would be happy to assist you.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
*Over two years in a large large (N=1,133) head-to-head Phase III study vs. teriflunomide 14mg in adult patients with active RMS.[^2]
RMS, relapsing multiple sclerosis.